IPO Overview & What to Expect
Picard Medical, Inc. is in the process of going public via an IPO on the NYSE American (formerly NYSE MKT) under the ticker PMI.AlphaStreetStockAnalysisSimply Wall St
Key IPO Details:
- Listing Date: The IPO is expected to take place August 22, 2025.BenzingaIPOScoop
- Price Range: The share price is set between US $3.50 and US $4.50.AlphaStreetStockAnalysisIPOScoop
- Shares Offered: Between 4.25 million and 4.3 million shares, aiming to raise roughly $17 million at the midpoint.StockAnalysisIPOScoopRenaissance Capital
- Use of Proceeds: Capital will support operations, expand market reach (notably via a joint venture in China), fund R&D, and boost sales and marketing for its artificial heart system.AlphaStreet
- Lock-Up Period: Insiders are bound by a 180-day lock-up, expiring approximately February 18, 2026.BenzingaWebull
Company Background & Strategic Vision
Picard Medical is the holding company for SynCardia Systems, which produces the only FDA- and Health Canada–approved implantable total artificial heart (SynCardia TAH), used as a bridge to heart transplantation in patients with severe biventricular failure.AlphaStreetStockAnalysis+1IPOScoop
- Global Reach: Over 2,100 SynCardia TAHs have been implanted across 27 countries.StockAnalysisIPOScoop
- Next-Gen Product: The company is developing a fully implantable artificial heart (codenamed Emperor), which would eliminate the need for external pneumatic drivers. Prototypes are currently undergoing non-clinical testing, with potential FDA approval targeted around 2028.IPOScoop
Picard Medical, Inc. (PMI) Financial Snapshot (Recent Financials)
- Q1 2025 (ending March 31):
- Net Sales: $0.62 million (versus $1.98 million in Q1 2024)
- Net Loss: $5.56 million (or $0.80 per share), compared to a $1.95 million loss (or $0.33 per share) in the prior year quarter.AlphaStreet
- Full-Year (TTM):
- Revenue: ~$4 million
- Net Loss: ~$21.1 million
- Market Cap: Around $289 million
- Shares Outstanding: Approximately 72 million.IPOScoopSimply Wall StRenaissance Capital
Picard Medical emphasizes that its future growth hinges on successful commercialization of its total artificial heart systems, expansion into new markets (notably China), and progression of its implantable TAH development.
Upcoming Timeline at a Glance Picard Medical, Inc. (PMI)
| Date | Event |
|---|---|
| Aug 22, 2025 | IPO expected to commence on NYSE American |
| Feb 18, 2026 | End of insider 180-day lock-up period |
| 2028 (Target) | Potential FDA submission/approval for fully implantable TAH |
📊 Picard Medical, Inc. (PMI) — IPO Overview
Proposed Symbol: PMI
Exchange: NYSE American (NYSE MKT)
Share Price Range: $3.50 – $4.50
Shares Offered: 4,250,000 (+ 637,500 overallotment)
Offer Amount: ~$22 million
Shares Outstanding (post-IPO): ~72.3 million
Market Cap (at midpoint): ~$295 million
Lockup Period: 180 days
Employees: 75 (as of Aug 6, 2025)
State of Inc.: Delaware
Fiscal Year End: December 31
Headquarters: 1992 E. Silverlake Rd., Tucson, AZ 85713
Phone: (520) 308-0796
Website: www.syncardia.com
CEO: Patrick NJ Schnegelsberg
🏥Picard Medical, Inc. (PMI) Company Description
Picard Medical, Inc. (PMI) is a holding company that wholly owns SynCardia Systems, LLC, a pioneering medical technology company.
- Flagship Product: The SynCardia Total Artificial Heart (TAH) — the only FDA- and Health Canada–approved implantable total artificial heart.
- Clinical Impact: Over 2,100 implants across 27 countries, primarily used as a Bridge to Transplantation (BTT) for patients with severe biventricular heart failure.
- Pipeline:
- Near-Term Goals: Extend indications beyond BTT to include Bridge to Candidacy (BTC) and long-term use (>2 years).
- Next-Gen Development: The Emperor Fully Implantable TAH — designed to eliminate external pneumatic drivers. Currently in non-clinical testing, with FDA approval targeted around 2028.
🌍Picard Medical, Inc. (PMI) Market & Competitive Landscape
- Approved Competitors:
- Carmat SA (France) — CE-marked Aeson TAH in Europe.
- In Development:
- BiVACOR, Inc. — Began early-stage human trials in July 2024.
- Alternatives Used by Cardiologists:
- Dual LVADs (e.g., Abbott’s HeartMate 3), ECMO, or temporary mechanical circulatory support.
- Key Differentiator: SynCardia TAH replaces both ventricles, supports discharge from hospital, and has decades of clinical use advantage.
📈 Investment Highlights
✅ Only FDA-approved total artificial heart in the U.S. and Canada.
✅ Large unmet need: ~6.5M Americans with heart failure; donor hearts <5,000 annually.
✅ First-mover advantage with over 2,100 implants and 20+ years of clinical history.
✅ Pipeline aimed at fully implantable heart (Emperor TAH) with multibillion-dollar market potential.
⚠️ Risks & Challenges
- Financials: Q1 2025 net sales $0.62M (down from $1.98M YoY); net loss $5.6M.
- Cash Burn: ~$21M net loss in the last twelve months.
- Execution Risk: Success depends on commercial growth, new FDA approvals, and R&D timelines.
- Competition: Emerging players (Carmat, BiVACOR) and evolving LVAD use.
⏱️ Key IPO Details & Timeline
| Event | Date |
|---|---|
| IPO Date | Aug 22, 2025 |
| Lockup Expiration | ~Feb 18, 2026 |
| Target FDA Approval (Emperor TAH) | 2028 |
💰 Picard Medical, Inc. (PMI) — Financial Snapshot
Period: Q1 2025 (ended March 31, 2025)
| Metric | Amount |
|---|---|
| Revenue | $620,000 |
| Net Income (Loss) | ($5,561,000) |
| Total Assets | $11,963,000 |
| Total Liabilities | $40,620,000 |
| Stockholders’ Equity | ($48,922,000) |
Key Takeaways:
- 📉 Negative equity position (≈ –$49M) → liabilities far exceed assets.
- 💸 High cash burn: Net loss nearly 9x revenue in Q1.
- ⚖️ Balance sheet strain: Liabilities outweigh assets by ~3.4x.
- 🚨 Profitability not in sight; IPO proceeds critical to funding operations, R&D, and commercialization.
📝 Picard Medical, Inc. (PMI) Company Filings (SEC S-1 History)
| Date Received | Form Type | Notes |
|---|---|---|
| 04/01/2025 | S-1 | Initial registration filing |
| 04/25/2025 | S-1/A | First amendment |
| 05/09/2025 | S-1/A | Update to disclosures |
| 05/23/2025 | S-1/A | Further refinements |
| 07/14/2025 | S-1/A | Financial updates |
| 07/18/2025 | S-1/A | Adjustments to offering |
| 07/30/2025 | S-1/A | Pricing/terms fine-tuning |
| 08/06/2025 | S-1/A | Final amendment before IPO |
Status: Filed and amended multiple times → indicates ongoing negotiation with SEC, finalizing terms ahead of Aug 22, 2025 IPO.
📊 Investor Lens: Quick Sentiment Snapshot
✅ Bull Case (Positive Sentiment)
- Only FDA/Health Canada–approved total artificial heart → massive unmet demand.
- 2,100+ implants, global clinical experience, strong IP moat.
- IPO proceeds provide runway to advance “Emperor” fully implantable TAH (target FDA approval 2028).
⚠️ Bear Case (Negative Sentiment)
- Severe financial weakness (negative equity, high losses).
- Revenue is small and declining YoY.
- Commercial growth uncertain; reliant on regulatory milestones.
- Faces emerging competition (Carmat, BiVACOR).